Discovery awaits you at the 81ST Scientific Sessions - Advance Program scientificsessions.diabetes.org #ADA2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
VIRTUAL | JUNE 25–29, 2021 Discovery awaits you at the 81ST Scientific Sessions Advance Program scientificsessions.diabetes.org #ADA2021
ADVANCE PROGRAM
ABOUT THE MEETING All pre-recorded sessions will be 2021 NATIONAL SCIENTIFIC &
The Scientific Sessions offers released during the original scheduled HEALTH CARE ACHIEVEMENT
researchers and health care times over the five-day meeting, AWARD RECIPIENTS
professionals the unique opportunity beginning on Friday, June 25 at Banting Medal for Scientific
to share ideas and learn about 11:30 a.m., and concluding on Achievement
the significant advances and Tuesday, June 29 at 12:15 p.m. ET Jens J. Holst, MD, DMSc
breakthroughs in diabetes. (United States Eastern Time). All
registered attendees will receive Outstanding Scientific Achievement
Participants will receive exclusive unlimited access to all virtual content Award
access to more than 180 sessions and for 90-days after the meeting. Kristen J. Nadeau, MD, MSPH
1,000 original research presentations, Albert Renold Award
take part in provocative and engaging LEARNING OBJECTIVES Bruce M. Spiegelman, PhD
exchanges with leading diabetes The Scientific Sessions offers Outstanding Achievement in Clinical
experts, expand their professional comprehensive educational Diabetes Award
networks, and so much more. programming covering the latest in Hans-Henrik D. Parving, MD
the field of diabetes. The program is
The program is categorized into Outstanding Educator in Diabetes
designed for physicians, scientists,
eight distinct theme areas, allowing Award
researchers, nurses, dietitians,
participants to focus on their specialty Denise Charron-Prochownik, PhD,
pharmacists, psychologists, and other
or expand their knowledge in other CPNP
health care professionals.
areas. Outstanding Physician Clinician in
At the conclusion of this activity Diabetes Award
Theme Areas:
attendees will be able to: Silvio E. Inzucchi, MD
n Acute and Chronic Complications
n Identify the 2021 ADA Standards Harold Rifkin Award for
n Behavioral Medicine, Clinical of Care for classifying, diagnosing,
Nutrition, Education, and Exercise Distinguished International Service
preventing, and treating prediabetes in the Cause of Diabetes
n Clinical Diabetes/Therapeutics and diabetes Juleen R. Zierath, PhD
n Epidemiology/Genetics n Assess non-pharmacologic Kelly West Award for Outstanding
n Immunology/Transplantation treatment options for individualizing Achievement in Epidemiology
n Insulin Action/Molecular Metabolism treatment protocols for the Nicholas Wareham, MD, MPH
management of hyperglycemia and
n Integrated Physiology/Obesity
hypoglycemia 2021 INTEREST GROUP
n Islet Biology/Insulin Secretion
n Apply clinical decision-making tools LECTURE AWARDS
Don’t miss this opportunity to join your to the assessment and treatment of
Roger Pecoraro Award
colleagues at the world’s largest, most the complications related to diabetes
(Interest Group on Foot Care)
prestigious meeting on diabetes—The n Develop a more aggressive, effective, Edward J. Boyko, MD, MPH
American Diabetes Association’s physiological, psychological, and
behavioral treatment plan for patients Edwin Bierman Award
81st Scientific Sessions (#ADA2021)!
with diabetes (Interest Group on Complications)
Russell Debose-Boyd, PhD
FORMAT AND DATES n Cite the research into current,
While we were hoping to meet in emerging, and novel therapies for Norbert Freinkel Award
person this June, the health and type 1 and type 2 diabetes (Interest Group on Pregnancy)
safety of our attendees, staff, and Denice Feig, MD, MSc, FRCPC
n Discuss proven education strategies
exhibitors remains the top priority of for increasing the impact of diabetes Richard R. Rubin Award
the American Diabetes Association® education with individual patients (Interest Group on Behavioral Medicine
(ADA)—which is why we have made n Interpret the latest findings in the & Psychology)
the decision to transition the 2021 areas of epidemiology, genetics, David G. Marrero, PhD
Scientific Sessions to a virtual meeting. immunology, transplantation, Lois Jovanovic Transformative
and islet biology as they relate to Woman in Diabetes Award
You can rest assured that the virtual
diabetes (Women’s Interprofessional Network of
81st Scientific Sessions will continue
to offer the latest groundbreaking the American Diabetes Association)
science that you have come to expect Linda M. Siminerio, RN, PhD, CDE
from the ADA.
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021
2ADVANCE PROGRAM
MEETING HIGHLIGHTS Oral Presentations Scientific Sessions Mobile App
Highly Anticipated Study Abstracts selected for oral Access the meeting on-the-go.
Announcements presentation are considered to be the Download the Scientific Sessions
In addition to the over 180 sessions best of the thousands of abstracts Mobile App to access information on
and 1,000 original research submitted to the Scientific Sessions. your smartphone, tablet, or handheld
presentations, we are excited to Choose from over 330 original device. The app is scheduled to be
announce that new data or updates to presentations highlighting the most released on May 28.
the following studies will be presented innovative research not found at any
other meeting. Visit scientificsessions.diabetes.org at
during the meeting: that time for download details.
n Efficacy and Safety of Dapagliflozin Virtual Poster Hall
in Patients with and without Type 2 View more than 1,000 ePosters and Exhibit Hall
Diabetes Hospitalized with listen to recorded audio (if provided by Visit our Exhibit Hall to receive
COVID-19—Results from the DARE- the presenter) in the virtual poster hall. information on products and services
19 Global Randomized Controlled ePosters will be available for viewing that will enhance your understanding
Trial throughout the entire meeting. of the latest advancements in
pharmaceuticals, devices, imaging
n Results of the Glycemic Reduction and services important to high-quality
Approaches in Diabetes—A Abstract Availability
Abstract titles are scheduled to be patient care.
Comparative Effectiveness (GRADE)
Study available via the Scientific Sessions
App on Friday, May 28. Embargoed Product Theaters
n Tirzepatide—A Novel Dual GIP/ text of abstracts will be made Product Theaters will showcase
GLP-1RA—Results from the First available on Tuesday, June 22. industry experts who will provide
Phase 3 SURPASS Clinical Trials Note: The abstract embargo still insight into diabetes services and
applies; however, abstracts are products and demonstrate innovate
n Update on SCORED and SOLOIST
made available to attendees to assist equipment and technologies.
Cardiovascular and Kidney
Outcomes Trials in creating their itineraries for the
meeting. Corporate Symposia
Corporate Symposia are satellite
Mini-Symposia
Earn Continuing Education Credits programs that are planned and
Mini-Symposia are 1-hour sessions
Continuing Education Credit is conducted by the corporate
that normally include 1-2 speakers.
available for physicians, family community in conjunction with the
Speakers present on a topic for a
physicians, international physicians, Scientific Sessions. These programs
maximum of 20 minutes with the
physician assistants, nurses, provide attendees with additional
remainder of the time devoted to
pharmacists, dietitians, psychologists, education.
questions and discussion with the
audience. social workers, and certified diabetes
care and education specialists.
Professional Interest Groups
You’ll have the opportunity to earn
Professional Interest Group
34.25 CE credits during the Live
Discussions are held Saturday,
Virtual Meeting (June 25-29) AND
Sunday, and Monday. Expect
up to 340 CE credits are available
lively conversations, dialogue, and
during the Post-Meeting Archive
debate with professionals in your
(June 30-September 29).
specialty such as islet biology, quality
improvement, and technology.
Learn more and join two groups
today at professional.diabetes.org/
interestgroups.
IMPORTANT DATES TO REMEMBER
Last day to register at the Advance rate May 13
Last day to cancel meeting registration and receive
a partial refund (50% of registration fee) May 13
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021
3ADVANCE PROGRAM
Women’s Inter-professional Network presenter perspectives on their own PHOTOGRAPhY/SOCIAL
The Women’s Interprofessional presentations, and check back after MEDIA
Network of the American Diabetes the meeting for continued coverage Photography
Association (#WINADA) is our through September. The site will be Allowing photographs of presentation
members-only network for female updated hourly during the Scientific slides at the Scientific Sessions will
clinicians, scientists, educators, and Sessions and will include a full be at the discretion of the presenter/
other professionals in diabetes. WIN calendar of Industry-Supported study author. Each presenter/study
ADA will host multiple events at the Symposia and Innovation Theaters. author will announce, verbally and
Scientific Sessions, including an Access ADAMeetingNews.org through visually on a slide at the beginning
interactive discussion on the long-term your web browser or the Scientific of their presentation, whether or
professional impact of COVID-19 and Sessions Mobile App (available on iOS not they approve of photos/screen
a networking reception. and Android). captures being taken of their slides. If
allowed, attendees may take photos/
Learn more and become a PROFESSIONAL MEMBERSHIP screen captures during presentations
WIN ADA member today at
Professional membership in the provided that they are for personal,
professional.diabetes.org/winada.
American Diabetes Association noncommercial use and are not for
provides you with cutting- publication or rebroadcast without
5K@ADA
edge research and professional the express written permission of the
Join us for the 5K@ADA Virtual
development resources that help author.
Challenge anytime during June 25–27.
you meet continuing education
Join people from across the globe and
requirements and stay on top of Social Media
register today at ada5k.com.
changes in diabetes treatment and The ADA encourages the use of social
care. Benefits include: media, when following the above
Shop Diabetes Store
n Subscriptions to ADA’s peer- photo policy and within embargo
Visit the Shop Diabetes Store at restrictions, to update followers on
reviewed and high impact scientific
shopdiabetes.org and save 30% on all the latest news coming from the
journals
books and official American Diabetes Scientific Sessions. To engage on
Association merchandise. Every n Save on registrations to Scientific
social media be sure to use the official
purchase supports diabetes research, Sessions and the Advanced
meeting hashtag, #ADA2021, in all of
advocacy, and education programs. Postgraduate course
your posts. You can also follow these
n Attend free members-only webinars channels for meeting updates:
ADA Meeting News to get hands-on tips to improve n Twitter: @ADA_DiabetesPro and
Don’t miss the groundbreaking diabetes care @AmDiabetesAssn
science from the Virtual 81st n Join two of 16 Professional Interest
Scientific Sessions by visiting the
n Facebook: @DiabetesPro and
Groups for career development and @AmericanDiabetesAssociation
meeting’s official online news source, collaboration with others in your
ADAMeetingNews.org. Read live specialty
n Instagram: @AmDiabetesAssn
coverage of virtual presentations, n LinkedIn: American-Diabetes-
get the latest news on upcoming Become a professional member at
Association
sessions, follow what’s being professional.diabetes.org/join.
talked about on social media, read
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021
4ADVANCE PROGRAM
REGISTRATION RATES
Advance Final
Category 3/12/21 - 5/13/21 5/14/21 - 9/29/21
Member* $449 $499
Non-Member $649 $699
Student/Resident/Fellow $159 $189
*To qualify for the Member rate your Medicine and Science or Health Care and Education Membership must be active through
June 30, 2021 at the time of registration.
REGISTER EARLY REGISTRATION CATEGORIES Media Registration
The first 4,000 domestic attendees Member The ADA provides complimentary
to register for the meeting will receive Medicine and Science or Health access to the Scientific Sessions to
a Welcome Box delivered to their Care and Education Professional credentialed members of the media,
designated mailing address prior to Members. including print, broadcast, and online
the start of the meeting. Each box media for the express purpose of
will include promotional items to add Have your Professional Member ID gathering news and information to
exciting physical elements to the number available to register for the produce press coverage of the 81st
virtual program. meeting as a member. Scientific Sessions.
Non-Member Media representatives welcome to
Refer Your Colleagues. Reward attend include reporters, writers,
Yourself For those who are not Medicine
and Science or Health Care and photographers, and videographers.
Share your interest in the science and News organizations seeking media
reward yourself with prizes! From now Education Professional Members.
credentials must be represented by
until June 24, registered attendees Become a member when you editorial staff.
who refer the highest number of new register for the Scientific Sessions
colleagues, or those who haven’t and save up to $200 on your For further information regarding
attended the Scientific Sessions registration. registration eligibility and
within the past two years, will have submission requirements for
the opportunity to win round trip Student/Resident/Fellow your news organization, contact
coach air travel, four nights hotel, and Available to those currently enrolled in SciSessionsPress@diabetes.org with
complimentary meeting registration to one of these programs. Proof of status any questions.
attend the 82nd Scientific Sessions, in a program must be submitted in
June 3-7, 2022, in New Orleans, LA. Warning/Be Aware!
order to register.
In addition, the top five runner ups There are companies
with the most referred colleagues will that are claiming to
Register Online
be awarded complimentary meeting offer registration
Go to scientificsessions.diabetes.
registration to the 82nd Scientific services for ADA’s
org and click on the “Registration Scientific Sessions,
Sessions in 2022. Information” tab. Online registration is which are not affiliated with ADA
To qualify, the referred colleague fast, easy, and secure. You will receive and do not offer any services on
must enter your name in the referral your confirmation letter and periodic our behalf. You may receive emails
question when registering for the updates via email. or phone calls from these companies
meeting. Prizes awarded must be urging you to register. Registration
redeemed for the 82nd Scientific Questions? should only be accessed from
Sessions and are not transferrable. Contact the ADA Registration Support scientificsessions.diabetes.org, and
Hotel accommodations provided are Center Monday through Friday, reserved through ADA’s official
at the discretion of the ADA. 9:00 a.m. to 7:00 p.m. (Eastern Time) registration provider, Convention
at 866-290-9910 (Toll Free U.S. & Management Resources, (CMR).
See full promotion terms and Canada) or +415-268-2086 If you do not see this logo on the
conditions. (International). Visit the ADA Support website, then they are not our
Center at https://reg.cmrus.com/ official provider!
ada2021/support.aspx.
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021
5ADVANCE PROGRAM
ACCREDITATION STATEMENTS Note: Upon submission of the online Psychologists
AND CONTINUING EDUCATION evaluation, the MOC points will be Continuing
CREDIT immediately transferred to the ABIM. Education
As previously stated and per the (CE) credits for
For questions regarding continuing
ABIM rules, the ADA does not have psychologists are provided through
education, please contact
access nor the ability to upload points the co-sponsorship of the American
professionaleducation@diabetes.org.
requested after the evaluation closes. Psychological Association (APA) Office
of Continuing Education in Psychology
Physicians, Nurses, and Pharmacists
Physicians from Europe (CEP). The APA CEP Office maintains
In support of
UEMS/ACCME CME credit responsibly for the content of the
improving patient
recognition: The American Medical programs.
care, the American
Association (AMA) has an agreement
Diabetes Association
of mutual recognition of CME credit Social Workers
is jointly accredited by the
with the UEMS. Under the terms of this As a Jointly
Accreditation Council for Continuing
agreement, the European Accreditation Accredited
Medical Education (ACCME), the
Council for Continuing Medical Organization,
Accreditation Council for Pharmacy
Education (EACCME), the accrediting the American Diabetes Association
Education (ACPE), and the American
arm of the UEMS, will convert CME is approved to offer social work
Nurses Credentialing Center (ANCC)
credit for live activities certified by the continuing education by the
to provide continuing education for the
AMA. Association of Social Work Boards
healthcare team.
(ASWB) Approved Continuing
This activity was planned by and for Family Physicians Education (ACE) program.
the healthcare team, and learners Application for CME credit has been Organizations, not individual courses,
will receive 34.25 Interprofessional filed with the American Academy of are approved under this program.
Continuing Education (IPCE) credit Family Physicians. Determination of State and provincial regulatory boards
for learning and change. credit is pending. have the final authority to determine
whether an individual course may be
Nurses: Pharmacotherapeutic change Physician Assistants accepted for continuing education
to CE credits offered up to 23. The American Diabetes credit. The American Diabetes
Association has been Association maintains responsibility for
Pharmacists: The Universal Activity
authorized by the this course. Social workers completing
Number is: JA4008193-0000-21-009-
American Academy of this course receive 34.25 continuing
L01-P.
PAs (AAPA) to award education credits.
Note for Pharmacists: Upon closing AAPA Category 1 CME credit for
of the online evaluation, the ADA activities planned in accordance with Certified Diabetes Educators
will upload the pharmacy-related AAPA CME Criteria. This activity is To satisfy the requirement for renewal
continuing education information designated for 34.25 AAPA Category of certification by continuing education
to CPE Monitor within 60 days. Per 1 CME credits. PAs should only claim for the National Certification Board
ACPE rules, the ADA does not have credit commensurate with the extent of for Diabetes Educators (NCBDE),
access nor the ability to upload credits their participation. continuing education activities must
requested after the evaluation closes. be diabetes related and approved
Dietitians by a provider on the NCBDE List of
Physicians for ABIM Maintenance of The American Diabetes Approved Providers (www.ncbde.org).
Certification Association is a Continuing NCBDE does not approve continuing
Successful Professional Education education. The American Diabetes
completion of (CPE) Accredited Provider Association is on the NCBDE List of
this CME activity, which includes with the Commission Approved Providers.
participation in the evaluation on Dietetic Registration (CDR).
component, enables the participant to Registered dietitians (RDs) and dietetic To Obtain Continuing Education
earn up to 34.25 Medical Knowledge technicians, registered (DTRs) will Credit
only MOC points in the American receive 34.25 continuing professional Certificates of Completion/Attendance
Board of Internal Medicine’s (ABIM) education units (CPEUs) for are provided to registered attendees
Maintenance of Certification (MOC) completion of this program/material. based upon completion of the
program. It is the CME activity Activity Number: 161537. online evaluation. The link to the
provider’s responsibility to submit online evaluation will be emailed to
participant completion information to participants on June 25, 2021. The
ACCME for the purpose of granting continuing education evaluation
ABIM MOC credit. system will be available through
October 4, 2021.
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021
6Virtual Exhibits and Poster Hall: Available beginning at 11:30 a.m.
DAY-AT-A-GLANCE SCHEDULE
FRIDAY, JUNE 25, 2021
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
11:30 a.m.- Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium
12:30 p.m. The Impact of Executive Function Diabetes Prevention in Resources for Dietary Modulation of The Bile Acid Debate—What’s the
COVID-19 on Foot in Youth with Type 1 Vulnerable Populations Interpreting Genetic Nutrient Metabolism in Receptor FXR and the Hubbub about Beta-
Care in Diabetes Diabetes—Driven to Mini-Symposium Variants Associated Cancer Microbiome Cell Hubs?
Mini-Symposium Diabetes Distraction COVID-19, Diabetes, with Diabetes and
Intersection of Mini-Symposium and Pregnancy—The Obesity
Diabetes, Heart The Anatomy of Inter- Perfect Storm?
Failure, and Kidney disciplinary Integration
Disease—Challenges in Health Care
and New Insights Education
Mini-Symposium Mini-Symposium
Could Point-of-Care Carbohydrate Intake
Devices Prove Useful and Its Impact
in the Diagnosis of on Athletics and
Diabetic Neuropathy in Health—A Debate
Clinical Practice?
12:45 p.m.- Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium Mini-Symposium
1:45 p.m. We All Know What Diabetes “Diets” Are We There Yet? Diabetes and the Brain Debate—Should Debate—
Causes Hypoglycemia, since the Discovery Initiating SGLT2 across the Lifespan— Immune Intervention Intergenerational
Don’t We? of Insulin—Looking Inhibitors and/or Neurocognitive Deficits Trials Occur during the Transmission of
Mini-Symposium Back, Then to the GLP-1RAs in and Decline COVID-19 Pandemic? Obesity—Focus
COVID-19 and Future the Inpatient on the Womb or the
Lipids—What’s the Cardiovascular Setting Home?
Connection? Mini-Symposium Mini-Symposium
Mini-Symposium COVID-19 and Influence of Social
Identifying Patients Beyond—Viruses in Inequalities and Social
at Risk—Kidney Pediatric Diabetes Stress on Metabolic
Disease Surveillance in Health
Diabetes
Mini-Symposium
Diabetes Retinopathy
Detection and
Treatment in
Resource-Constrained
Areas
7Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
FRIDAY, JUNE 25, 2021 (CONTINUED)
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
2:00 p.m.- Symposium Symposium Symposium Symposium Symposium Symposium Symposium Symposium
4:00 p.m. Evidence-Based The Expanded Scope Screening for Health Care as a Innovations in Beta- Fructose Metabolism Autonomic Nervous Functional
Guidelines for Diabetes of the Diabetes Gestational Social Justice Issue Cell Replacement and Disease— System (ANS) Consequences of Islet
and Chronic Kidney Care and Education Diabetes—Is This in the Diagnosis Therapy Intestine, Microbiota, Control of Peripheral Non-beta Cells
Disease Specialist Your Final Answer? and Management of and Liver Metabolism and
Symposium Diabetes Metabolic Diseases
COVID-19 and
Diabetes—An
Update
Symposium
Mental Health
Disorders in Patients
with Diabetes—A
Most Challenging Mix
4:15 p.m.- Symposium Symposium Symposium Oral Presentations Symposium Oral Presentations Symposium Oral Presentations
6:15 p.m. A Primer on Diabetes The Molecular SGLT2is and GLP- Age, Sex, and When Time
Foot Management Transducers behind 1RAs—Are They Ethnicity—Impact Matters—The
for the Primary Care the Benefits of Worth It? on Type 1 Diabetes Influence of Time-
Provider Physical Activity Symposium Development Restricted Feeding
Oral Presentations Implementing
Type 1 Diabetes
Immune Intervention in
Clinical Practice
Oral Presentations
8Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
SATURDAY, JUNE 26, 2021
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
8:00 a.m.- Symposium Symposium Symposium Symposium Symposium Symposium Symposium
10:00 a.m. Practice-Changing Making Physical Activity (8:00 a.m.-9:00 a.m.) ADA Diabetes Care The Immune– Polycystic Ovary Beta-Cell Senescence/
Trials in Heart Failure Accessible and Doable “STEP” against Symposium— Metabolism Interface Syndrome (PCOS)— Stress
and Kidney Disease for Everyone Obesity—Once-Weekly Learning to Minimize Towards Personalized
with SGLT2 Inhibitors Symposium Semaglutide 2.4 mg Risks for People Medicine—Advances
Oral Presentations ADA Education Clinical Development with Diabetes in the in PCOS Diagnosis
Recognition Program Program for Weight COVID-19 Pandemic and Care
Symposium—VHA and Management Symposium
DoD Virtual Diabetes Symposium Joint ADA/Chinese
Self-Management Including Social Diabetes Society
Training (DSMT)—A Determinants of Health Symposium—Novel
Novel, Learner- in Diabetes Care Mechanisms and
Centered, Avatar- Symposium Targets
to-Avatar Remote Diabetes and
Alternative for Providing Brain Health
Remote Certified
Diabetes Education Symposium
Systemic Racism and
Disparities in Pediatric
Diabetes Management
10:15 a.m.-
ADA Chief Executive Officer Remarks; President, Health Care & Education Address; and Outstanding Educator in Diabetes Award Lecture
11:30 a.m.
11:30 a.m.- Professional Interest Professional Interest Professional Interest
12:30 p.m. Group Discussion Group Discussion on Group Discussion
on Exercise Clinical Centers and on Islet Biology,
Physiology—Exercise Programs— Development, and
in Post-COVID Here to Stay? Function—
Infection—ImplicationsHarnessing Telemedicine Rising Stars of Diabetes
for Treatment, Research, for Diabetes Care in Research
and Public Health the COVID-19 Era and
Professional Interest Beyond
Group Discussion on
Nutritional Science
and Metabolism—
Food, Nutrition, and
Insulin Actions
Mini-Symposium
Women’s
Interprofessional
Network of the ADA
(WIN ADA)—Long-
Term Professional
Impact of COVID-19
12:30 p.m.-
Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)
1:45 p.m.
9Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
SATURDAY, JUNE 26, 2021 (CONTINUED)
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
1:45 p.m.- Symposium Symposium Symposium Symposium Symposium Symposium Oral Presentations Symposium
3:45 p.m. The Pros and Cons of Diabetes through a Technology in Beyond Genome- Current Role Insulin at Its 100th ES-Derived Beta
New Approaches to Health Equity Lens Pregnancy— Wide Association of Pancreas Birthday Cells—From
Prevent and Manage (With Richard Continuous Glucose Studies— Transplantation in the Disease Modeling to
Hypoglycemia in R. Rubin Award Monitoring (CGM) and Understanding the Treatment of Diabetes Therapeutics
Diabetes Therapies Lecture) Beyond Function of Variants
Oral Presentations Oral Presentations Current Issues Associated with
(1:45 p.m.-2:45 p.m.) Diabetes
Edwin Bierman
Award Lecture Debate—Digital Oral Presentations
Coaching Systems for
Type 2 Diabetes—Are
They Worth the Cost?
Current Issues
(2:45 p.m.-3:45 p.m.)
Debate—Are the
Metabolic Benefits of
Roux-en-Y Gastric
Bypass Due to
Weight Loss Alone?
Oral Presentations
4:00 p.m.- Symposium Symposium Symposium Symposium Oral Presentations Oral Presentations Symposium Symposium
6:00 p.m. Resolving Key Carbohydrate Obesity and A Global Perspective Nutrient Sensing NIDDK Symposium—
Controversies in Counting—Still Useful Cardiovascular on Diabetes— and Macronutrient Heterogeneity in
Diabetic Neuropathy with New Technology? Disease in Type 1 Bidirectional Learning Metabolism Diabetes Mellitus—
Oral Presentations Diabetes for Lower- and Middle- Developing a More
Symposium Income and Higher- Stratified Medical
Debate—Joint ADA/ Income Countries Approach from the
AACC Presentation— Bench to Bedside
Point-of-Care Oral Presentations
HbA1c—Should We
Use It to Diagnose
Diabetes?
Oral Presentations
Norbert Freinkel
Award Lecture
10Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
SUNDAY, JUNE 27, 2021
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
8:00 a.m.- Symposium Symposium Symposium Oral Presentations Oral Presentations Symposium Symposium Oral Presentations
10:00 a.m. New Tools to Examine Preserving Mental Matchmaker, Emerging Paradigms ADA Diabetes
Diabetes-Related Health across the Matchmaker, Make Me of Uncoupled Symposium—New
Kidney Disease Lifespan of Living with a Match—Selecting Bioenergetics in Turf for the Other
Oral Presentations Diabetes (and during Glucose-Lowering Metabolic Disease Incretin—GIP
COVID-19) Combinations for Signaling in the Brain
Symposium Type 2 Diabetes and Effects on Food
Who Should Loop? Mellitus Intake and Energy
Pro/Cons Oral Presentations Balance
Oral Presentations
10:15 a.m.-
President, Medicine & Science Address and Banting Medal for Scientific Achievement
11:45 a.m.
12:00 p.m.- Professional Interest Professional Interest Professional Interest
1:00 p.m. Group Discussion Group Discussion on Group Discussion
on Diabetes and Behavioral Medicine on Diabetes in
Cardiovascular and Psychology— Youth—Identification
Disease—Are We Need More Mental and Management
We Going to Learn Health Providers! of Prediabetes in
More from Broader Growing the Behavioral Youth—Pros vs. Cons
Evaluations of New Diabetes Workforce
Glycemic Lowering Professional Interest
Medications Beyond Group Discussion
Cardiovascular on Diabetes Self-
Outcome (CVO) Trials? Management
Is It Time to Let Go of Education and
“CVO” Trials? Support (DSMES)—
Professional Interest Post-Pandemic Care
Group Discussion for Patients with
on Eye Health— Diabetes in a Diverse
Ocular Health Care by Population
Telehealth and Artificial
Intelligence (AI)
1:00 p.m.-
Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)
2:00 p.m.
11Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
SUNDAY, JUNE 27, 2021 (CONTINUED)
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
2:15 p.m.- Symposium Symposium Symposium Award Lecture Symposium Symposium Symposium
4:15 p.m. The Importance of Timing Is (2:15 p.m.-3:15 p.m.) (2:15 p.m.-3:00 p.m.) Personalized Medicine Health Disparities All Roads Lead to
Triglycerides Continues Everything—Meal Efficacy and Safety Kelly West Award for Immune Therapies among People with Insulin
to Emerge and Exercise Timing of Dapagliflozin in for Outstanding in Type 1 Diabetes Obesity
Oral Presentations and Your Circadian Patients with and Achievement in Oral Presentations
Clock without Type 2 Epidemiology Lecture
Symposium Diabetes Hospitalized
Aiming for Balance— with COVID-19—
Type 1 Diabetes and Results from the
Exercise Management DARE-19 Global
Perfected Randomized
Controlled Trial
Symposium
Reimagining Diabetes
Care in the Virtual
World
Symposium
Children with Type 2
Diabetes Are Not Just
Little Adults
Oral Presentations
4:30 p.m.- Symposium Symposium Symposium Symposium Symposium Symposium Symposium
6:30 p.m. Diabetes Retinal When COVID-19 Disrupting Endocrine Drugs and Novel Insights and Old Diabetes and What’s for Dinner?
Disease—Changing Clashes with Milieu of Pregnancy— Genetics— Controversies around Metabolism across the Dietary Interventions
Before Your Eyes Diabetes—Data and Mechanisms of Per- Pharmacogenomic Insulin and Glucagon- Lifespan and Beta-Cell Function
Oral Presentations Experiences Regarding and Polyfluoroalkyl Approaches to Like Signaling
the Impact on People Substances (PFAS) in Precision Diabetes
with Diabetes Maternal-Fetal Health Treatment
Symposium Symposium
Optimizing Health The Year in Review—
Equity—Solutions- Highlights of the
Based Approaches Past Year in Basic,
Translational, and
Clinical Sciences
Symposium
Remote Monitoring
and Use of
Telehealth—Lessons
Learned from a
Pandemic
Oral Presentations
12Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
MONDAY, JUNE 28, 2021
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
8:00 a.m.- Symposium Symposium Symposium Oral Presentations Symposium Symposium Oral Presentations Symposium
10:00 a.m. Surgical Considerations Diabetes Prevention— Automation and Clinical and Regulatory Fibrosis—At the Nuclear Control of
in Diabetes Foot Addressing Expanded Use of Hurdles Facing Islet Metabolism– Beta-Cell Function
Management Implementation Technology in the Transplantation Signaling Interface
Oral Presentations Challenges Inpatient Setting—
Oral Presentations An Update
Symposium
Is Continuous Glucose
Monitoring (CGM) an
Effective Diabetes
Management Tool in
Primary Care?
Symposium
Management of
Type 1 Diabetes in
Adults—2021 Draft
ADA/EASD Consensus
Report
Oral Presentations
10:10 a.m.-
National Scientific & Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture
11:45 a.m.
12:00 p.m.- Professional Interest Professional Interest Professional Interest
1:00 p.m. Group Discussion on Group Discussion Group Discussion
Diabetes Technology— on Public Health and on Immunology,
Understanding the Epidemiology— Immunogenetics, and
Current State of Apps Is Diabetes a Risk Factor Transplantation—
for Supporting Effective for Adverse Health Clinical Response
Diabetes Care Outcomes in Patients with Endotypes in
Professional Interest COVID-19? Type 1 Diabetes
Group Discussion
on Health Care
Delivery and Quality
Improvement—Don’t
Forget to Ramp Up and
Don’t Hesitate to Slow
Down—Clinical Inertia in
the Treatment of Diabetes
Professional Interest
Group Discussion
on Pregnancy and
Reproductive Health—
First Trimester Screening
for Diabetes—What Is
the Best Approach?
1:00 p.m.-
Session Break (Take this opportunity to visit the Virtual Exhibits and Poster Hall)
2:00 p.m.
13Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
MONDAY, JUNE 28, 2021 (CONTINUED)
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
2:15 p.m.- Symposium Symposium Symposium Symposium Symposium Symposium Symposium Oral Presentations
4:15 p.m. Neonatal Accelerating Care and Joint ADA/ISPAD Communication of Risk in T Cells in Diabetes— Interorgan Cross Talk— Environmental Exposures
Hypoglycemia— Education—Digital Symposium—General the Era of COVID-19— Past, Present, and Future Metabolites, Proteins, and and Susceptibility to
Overdiagnosed or Health and Diabetes Population Screening vs. Public Health and Public Extracellular Vesicles Obesity and Metabolic
Underestimated? Support—Patient and Targeted Screening for Trust Consequences—What
Oral Presentations Provider Perspectives Type 1 Diabetes Risk Are the Main Drivers?
Roger Pecoraro Award Symposium Oral Presentations
Lecture Management of
Atypical Diabetes
Oral Presentations
4:30 p.m.- Symposium Symposium Symposium Symposium Oral Presentations Symposium Symposium
6:30 p.m. Joint ADA/ASN The Diabetes Digital (4:30 p.m.-6:55 p.m.) Imagining How Genetics COVID-19, Diabetes, The Latest on Incretin/
Symposium—New Landscape through Results of the Glycemia Alters Risk of Diabetes and Obesity GPCR Signaling in the Islet
Therapies for Kidney a Psychosocial and Reduction Approaches Oral Presentations
Protection in Diabetes Behavioral Lens in Diabetes—A
Oral Presentations Oral Presentations Comparative Effectiveness
(GRADE) Study
Oral Presentations
14Virtual Exhibits and Poster Hall: Available throughout the Meeting
DAY-AT-A-GLANCE SCHEDULE
TUESDAY, JUNE 29, 2021
Behavioral Medicine,
Clinical Nutrition,
Acute and Chronic Education, and Clinical Diabetes/ Epidemiology/ Immunology/ Insulin Action/ Integrated Islet Biology/
Complications Exercise Therapeutics Genetics Transplantation Molecular Metabolism Physiology/Obesity Insulin Secretion
8:00 a.m.- Symposium Current Issues Symposium Symposium Symposium Symposium Symposium
10:00 a.m. (9:00 a.m.-10:00 a.m.) (8:00 a.m.-9:20 a.m.) (8:00 a.m.-9:30 a.m.) High Dimensional Single-Cell Insulin as a Driver of The Islet and Type 1
Translating Diabetes Debate—Precision Next Chapter in Data in Epidemiologic Perspectives on Cancer Diabetes
and Kidney Disease Nutrition—Are We Incretin-Based Research—Gentle Metabolic Tissue
Clinical Trial Findings There Yet? Therapies— Introduction to Function
into Clinical Practice Tirzepatide, a Novel Methods and Survey
Dual GIP/GLP-1 of Strengths and
Receptor Agonist— Limitations
Results from the First
Phase 3 SURPASS
Clinical Trials
10:15 a.m.- Symposium
12:15 p.m. Update on SCORED
and SOLOIST
Cardiovascular and
Kidney Outcomes Trials
15ADVANCE PROGRAM
SCIENTIFIC PROGRAM • The Anatomy of Interdisciplinary • Resources for Interpreting Genetic
Integration in Health Care Education Variants Associated with Diabetes
and Obesity
FRIDAY, JUNE 25 A Model for the Expanded Role of
the Diabetes Care and Education Common Metabolic Disease
11:30 a.m.-12:30 p.m. Specialist into Clinical Diabetes Care Knowledge Portal
Management Noël Burtt, PhD
• The Impact of COVID-19 on Foot Paul Sacks, MD
Care in Diabetes The TIGER Resource for Development
Panel Discussion—Professional and Therapy of Type 2 Diabetes
Effects of COVID-19 on the Delivery of Education and Development to Drive Miriam Cnop, MD, PhD
Diabetic Foot Care Integration—How Do We Teach and
Brian M. Schmidt, DPM ClinGen—Clinical Relevance of Genes
Beyond? and Variants
Utilizing Telemedicine in Diabetic Foot Jennifer A. LeBlanc, MS, RN, CDCES Erin M. Ramos, PhD, MPH
Care Nuha Ali El Sayed, MD, MMSc
Laura Shin, DPM, PhD Question and Discussion Period
Samar Hafida, MD
Question and Discussion Period Question and Discussion Period • Dietary Modulation of Nutrient
Metabolism in Cancer
• Intersection of Diabetes, Heart • Carbohydrate Intake and Its
Failure, and Kidney Disease— Obesity and Cancer—A Metabolic
Impact on Athletics and Health—
Challenges and New Insights A Debate Connection?
Gen-sheng Feng, PhD
Heart Failure in Diabetes—New High/Normal Carbohydrate Intake
Therapeutic Insights Optimizes Performance and Glycemia Molecular Mechanisms Driving Dietary
Biykem Bozkurt, MD, PhD, FHFSA, James P. Morton, PhD Cancer Therapy
FACC, FAHA, FACP Christian Metallo, PhD
Low Carbohydrate Intake Optimizes
Diabetic Kidney Disease—What Is on Performance and Glycemia Question and Discussion Period
the Horizon? Dominic D’Agostino, PhD
Harriette Van Spall, MD, MPH • The Bile Acid Receptor FXR and
Question and Discussion Period the Microbiome
Combination Therapy with SGLT2i and
GLP-1RA in Mitigating Cardiorenal • Diabetes Prevention in Vulnerable Probiotics and Bile Acids
Metabolic Risk Populations Yu-Jui Yvonne Wan, PhD
Vanita R. Aroda, MD Effects of Medicaid Coverage on Gut Microbiota and FXR
Question and Discussion Period the Diabetes Prevention Program in Antonio Moschetta, MD, PhD
California Pharmacologic Utilization of Bile Acid-
• Could Point-of-Care Devices Prove O. Kenrik Duru, MD, MSHS FXR Pathway to Treat Nonalcoholic
Useful in the Diagnosis of Diabetic U.S. State Efforts to Sustain the Steatohepatitis
Neuropathy in Clinical Practice? National Diabetes Prevention Program Grace L. Guo, MBBS, PhD
Yes Gia E. Rutledge, MPH Question and Discussion Period
Bruce A. Perkins, MD, MPH Diabetes Prevention in the Indian Health
No • Debate—What’s the Hubbub about
Service
Brian C. Callaghan, MD, MS Beta-Cell Hubs?
Ann Bullock, MD
Question and Discussion Period Hubs Are Real
Question and Discussion Period
Guy A. Rutter, PhD
• Executive Function in Youth with • COVID-19, Diabetes, and Hubs Are Not Real
Type 1 Diabetes—Driven to Pregnancy—The Perfect Patrik Rorsman, BM, PhD, FRS,
Diabetes Distraction Storm? FMedSci
Executive Functioning, Symptoms of Diagnosis and Management of Question and Discussion Period
Depression and Anxiety, Adherence, Diabetes in Pregnancy during the
and Glycemic Control in Youth with COVID-19 Pandemic 12:45 p.m.-1:45 p.m.
Type 1 Diabetes David McIntyre, MD, FRACP
Danny C. Duke, PhD • We All Know What Causes
Telemedicine for Management Hypoglycemia, Don’t We?
Executive Functioning in Context— of Diabetes in Pregnancy during
Risk and Protective Factors Heterogeneity of Responses to
COVID-19 and Beyond
Eveline R. Goethals, PhD Hypoglycemia—Lessons from Animal
Noelia Zork, MD
Models
Work in Progress—Developmental Question and Discussion Period Candace M. Reno, PhD
Trajectories of Executive Function
across Adolescence Disparity of Risk for Impaired
Maartje de Wit, PhD Awareness of Hypoglycemia and
Severe Hypoglycemia—Exploring the
Clinical Strategies for Identifying Human Situation
Executive Function Problems and Using Amir Moheet, MBBS
Diabetes Technology to Support Youth
with Type 1 Diabetes Question and Discussion Period
Rachel M. Wasserman, PhD
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021 Speakers and presentation titles
are subject to change.
16ADVANCE PROGRAM
• COVID-19 and Lipids—What’s the • Are We There Yet? Initiating SGLT2 • Debate—Intergenerational
Connection? Inhibitors and/or GLP-1RAs in the Transmission of Obesity—Focus on
Plasma Lipid Changes in Response to Inpatient Cardiovascular Setting the Womb or the Home?
COVID-19 Infection and Implications for Time to Consider Initiating SGLT2 Introduction
Outcomes Inhibitors and/or GLP-1RAs in Amy E. Rothberg, MD, PhD, DABOM
Kenneth Feingold, MD the Inpatient Cardiovascular Care Womb
Potential Role of Lipids and Lipid Setting—And Here’s How Peter Gluckman, ONZ, KNZM,
Therapies (Statins, Fibrates, HDL- Sandeep Das, MD, MPH FRSNZ, FMedSci, FRS
Raising Drugs) in Modulating COVID-19 Caution before Universally Home
Infections Recommending Initiation of SGLT2 Julie Lumeng, MD
Alan Remaley, MD Inhibitors and/or GLP-1RAs in the
Inpatient Cardiovascular Care Setting Question and Discussion Period
Question and Discussion Period
Jennifer B. Green, MD
• Influence of Social Inequalities
• Identifying Patients at Risk— Question and Discussion Period and Social Stress on Metabolic
Kidney Disease Surveillance in Health
Diabetes • COVID-19 and Beyond—Viruses
in Pediatric Diabetes Social Determinants of Metabolic
Barriers to Kidney Disease Awareness Health—Evidence from Human
and Testing in People with Diabetes Epidemiology of COVID-19 and Populations
Chi Chu, MD Pediatric Diabetes—New-Onset/ Mika Kivimäki, PhD
Geospatial Approach to Chronic Kidney Diabetic Ketoacidosis
Social Determinants of Metabolic
Disease Surveillance in Diabetes— Mary Pat Gallagher, MD
Health—Evidence from Animal Models
Identifying Disparities and Hotspots What’s New in Type 1 Diabetes Carol Shively, PhD
Xiaosong Zhang, MS Epidemiology? A View from
Question and Discussion Period
Question and Discussion Period the Virology World
Kendra Vehik, PhD, MPH
2:00 p.m.-4:00 p.m.
• Diabetes Retinopathy Detection and Behavioral Interventions for Pediatric
Treatment in Resource-Constrained Diabetes during COVID-19 • Evidence-Based Guidelines for
Areas Carrie Tully, PhD Diabetes and Chronic Kidney
Implementing a Diabetes Retinopathy Question and Discussion Period Disease
Referral Network and Treatment in Living with Diabetes and Chronic
Peru • Diabetes and the Brain across the Kidney Disease
Omar Salamanca, MD Lifespan—Neurocognitive Deficits Tami Sadusky, BS, MBA
Implementing a Diabetes Retinopathy and Decline New Kidney Disease Improving Global
Research Network and Treatment in Prevention of Cognitive Impairment Outcomes (KDIGO) Guideline for
Latin America in Diabetes Management of Diabetes in Chronic
J. Fernando Arevalo, MD, PhD, FACS Anna Marseglia, PhD Kidney Disease
Question and Discussion Period Diabetes and the Developing Brain Luiza Caramori, MD, MSc, PhD
Fergus Cameron, FRACP, MD How Do the ADA, EASD, and KDIGO
• Diabetes “Diets” since the Discovery Question and Discussion Period Guidelines for Diabetes and Chronic
of Insulin—Looking Back, Then to Kidney Disease Compare?
the Future • Debate—Should Immune John B. Buse, MD, PhD
1921 to 1970s—Starvation Diets to Intervention Trials Occur during the How Will New Clinical Trials Affect
the Exchange System COVID-19 Pandemic? Evidence-Based Care for People with
Melinda D. Maryniuk, MEd, RDN, For—Type 1 Diabetes Immune Diabetes and Kidney Disease?
CDCES Intervention Trials during COVID-19 Peter Rossing, MD, DMSc
1980s to 2021—Prescribed Carla Greenbaum, MD
Macronutrient Percentages to Person- Against—Type 1 Diabetes Immune
Centered Approaches and Beyond Intervention Trials during COVID-19
Hope Warshaw, MMSc, RD, CDCES Adriana Weinberg, MD
Question and Discussion Period Question and Discussion Period
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021 Speakers and presentation titles
are subject to change.
17ADVANCE PROGRAM
• The Expanded Scope of the • Mental Health Disorders in Patients • Fructose Metabolism and Disease—
Diabetes Care and Education with Diabetes—A Most Challenging Intestine, Microbiota, and Liver
Specialist Mix Microbial Fructose Fermentation and
Outcomes of Digital Health—Lessons Depression in Patients with Metabolic Disease
Learned Diabetes—Prevalence, Impact on Kathryn E. Wellen, PhD
Nicole Bereolos, PhD, MPH, MSCP, Glycemic Control, and Strategies for Just Passing Through—Pre- and
CDCES Comanagement Postportal Fructose Metabolism
Preparing Diabetes Care and Education Jeffrey S. Gonzalez, PhD Cholsoon Jang, PhD
Specialists in 2021 and Beyond Challenges in Managing Diabetes in Fructose—Fueling the Fire of Tissue
Jane K. Dickinson, RN, PhD, CDCES Patients with Psychotic Disorders Injury in Nonalcoholic Fatty Liver
Pharmacy—Increase Access to Lydia Chwastiak, MD, MPH Disease
Diabetes Self-Management and Practical Approaches for Eating Michael Karin, PhD
Support Services on the Front Lines Disorders in Diabetes Poised for Trouble—The Challenge
Staci-Marie Norman, PharmD, CDE Ann E. Goebel-Fabbri, PhD Posed by Excess Fructose
Integrating Mental Health Strategies Anxiety Disorders and Diabetes—What Mark A. Herman, MD
into Practice Is the Relationship?
Susan Guzman, PhD Tina Drossos, PhD • Autonomic Nervous System (ANS)
Control of Peripheral Metabolism
• Screening for Gestational • Health Care as a Social Justice Issue and Metabolic Diseases
Diabetes—Is This Your Final in the Diagnosis and Management of Sex Differences in the ANS Control of
Answer? Diabetes Energy Expenditure
Gestational Diabetes Mellitus Ten Years of the Affordable Care Act— Stephanie Correa, PhD
Screening Strategies—Answers from Implications for Diabetes Diagnosis and Sympathetic Neuroimmunity in Obesity
Randomized Controlled Trials Management Ana Domingos, PhD
Christina M. Scifres, MD J. Frank Wharam, MD, MPH
Striatal Dopamine Controls Hepatic
Gestational Diabetes Mellitus Screening Diabetes, Social Vulnerability, and Glucose Production via the ANS
Strategies—Can We Get Pragmatic Health Outcomes Susanne E. La Fleur, PhD
Answers? Shivani Agarwal, MD, MPH
Teresa Hillier, MD, MS ANS Control of Adipose Tissue
Disentangling Social and Biological Risk Function
Preanalytical Blood Samples Handling Factors from a Social Epidemiology Heike Muenzberg-Gruening, PhD
during Gestational Diabetes Testing— Perspective
How Much Does It Change Results? Shakira F. Suglia, ScD, MS • Functional Consequences of Islet
Christopher J. Nolan, PhD, FRACP Racism, Discrimination, and Health Non-beta Cells
Should We Have Different Gestational Care in Diabetes Arginine Vasopressin (AVP) Regulation
Diabetes Mellitus Screening Strategies TBD of Glucagon Secretion
Depending on Prepregnancy Body Innovation in Health Care Financing to Linford J.B. Briant, PhD
Mass Index and Other Risk Factors? Mitigate Disparities in Diabetes
Dorte Møller Jensen, MD, PhD Metabolic Specialization of Alpha Cells
Monica E. Peek, MD, MPH, MSc and How Glucose Regulates Glucagon
Question and Discussion Period Question and Discussion Period Secretion
Jakob G. Knudsen, PhD
• COVID-19 and Diabetes—An • Innovations in Beta-Cell
Update Epsilon Cells
Replacement Therapy Jenny Tong, MD, MPH
Role of Hyperglycemia on COVID-19 Advances in Beta-Cell Replacement
Outcomes Delta-Cell Regulation of Islet Hormone
from the JDRF Consortium Secretion and Beta-Cell Replication
Alberto Coppelli, MD Esther Latres, PhD Vincent Poitout, DVM, PhD
COVID-19 and New-Onset Diabetes— Immunomodulatory Strategies in
Unmasking Type 2 Diabetes, Triggering Beta-Cell Transplantation 4:15 p.m.-6:15 p.m.
Autoimmunity, or Both? James M. Gardner, MD, PhD
Francesco Rubino, MD • A Primer on Diabetes Foot
Progress in Stem Cell-Derived Islets Management for the Primary Care
Managing and Preventing Diabetic Quinn P. Peterson, PhD
Ketoacidosis during the COVID-19 Provider
Pandemic Why Safety, Quality, and Value Matter in
Bruce W. Bode, MD the Management of the Diabetic Foot
Remote Monitoring of COVID-19 Priti Lakhani, DPM
Patients via Continuous Glucose The Three-Minute Diabetes Foot Exam
Monitoring for the Primary Care Provider
Francisco J. Pasquel, MD, MPH John D. Miller, DPM, DABFAS
How to Make the Multispecialty Team
Approach Work for Your Patients with
Diabetes
Rachel H. Albright, DPM, MPH
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021 Speakers and presentation titles
are subject to change.
18ADVANCE PROGRAM
• The Molecular Transducers behind • When Time Matters—The Influence • Making Physical Activity Accessible
the Benefits of Physical Activity of Time-Restricted Feeding and Doable for Everyone
MoTrPAC—Overview of Research Timing of Food Intake and Fasting— Home-Based Exercise and Other
on Molecular Transducers of Physical Circadian Rhythms and Biological Strategies to Remove Barriers to
Activity Mechanisms That Mediate Health Physical Activity
Wendy M. Kohrt, PhD Benefits Matthew Cocks, PhD
Preclinical Animal Studies—Molecular Dorothy D. Sears, PhD Reducing and Breaking Up Sitting
Responses to Acute Exercise and Metabolic Response to Time-Restricted Time—Does This Work?
Training Feeding David Dunstan, PhD
Karyn A. Esser, PhD Amandine Chaix, PhD Aiming High—How Feasible Is
Human Clinical Studies—Molecular Impact of Intermittent Fasting on High-Intensity or Interval Training for
Responses to Acute Exercise and Health, Aging, and Disease Everyone?
Training Leonie Heilbronn, PhD Jonathan P. Little, PhD
Bret H. Goodpaster, PhD Drug Metabolism and Timing How Can We Get Everyone Active?
The “Omics” Approach—Responses Manjunath Pai, PharmD Stop Telling, Start Listening
to Acute Exercise and Training How and Why Would Time-Restricted Mary Jung, PhD
K. Sreekumaran Nair, MD, PhD Feeding Lead to Weight Loss in
Humans? Results of Clinical Trials and • ADA Education Recognition Program
• SGLT2is and GLP-1RAs—Are They Practical Considerations Symposium—VHA and DoD Virtual
Worth It? Courtney M. Peterson, PhD, MSc, Diabetes Self-Management
SGLT2is and GLP-1RAs—What Are MA, MS Training (DSMT)—A Novel, Learner-
the Benefits? Centered, Avatar-to-Avatar Remote
Question and Discussion Period Alternative for Providing Remote
Jason Alexander, MD
Certified Diabetes Education
SGLT2is and GLP-1RAs—What Are • Oral Presentations
the Costs and Cost-Effectiveness? DSMT in the Virtual World—A
Hui Shao, MD, PhD Paradigm Shift for Diabetes Education?
SATURDAY, JUNE 26 Brian V. Burke, MD, FACP
SGLT2is and GLP-1RAs—Equity and
Value 8:00 a.m.-10:00 a.m. VHA’s Virtual DSMT—Training the
Aaron N. Winn, PhD Trainer for Virtual DSMT
• Practice-Changing Trials in Heart Mary M. Julius, RDN, LD, CDCES
Question and Discussion Period Failure and Kidney Disease with VA/DoD Virtual DSMT—Population
SGLT2 Inhibitors Served and the Patient Experience
• Implementing Type 1 Diabetes
Immune Intervention in Clinical Landmark Trials in Heart Failure Stephanie De Leon Ansley, MS, RD,
Practice Landmark Trials in Heart Failure— CSSD, LD, CDCES
Determining Genetic Risk DAPA-HF and EMPEROR-Reduced— The Nuts and Bolts of Building the VA
Ezio Bonifacio, PhD Do We Have All the Answers for SGLT2 Virtual Medical Center
Inhibitors in Heart Failure with Reduced Brian James, MEd
Antibody Screening for Type 1 Diabetes Ejection Fraction?
Andrea Steck, MD Carolyn S.P. Lam, MBBS, PhD • “STEP” against Obesity—Once-
Assessing Glycemia Landmark Trials in Heart Failure— Weekly Semaglutide 2.4 mg Clinical
Darrell M. Wilson, MD DELIVER and EMPEROR-Preserved— Development Program for Weight
Choosing an Intervention Will SGLT2 Inhibitors Succeed in Management
Stephen E. Gitelman, MD Heart Failure with Preserved Ejection Welcome and Introduction
Fraction? Lee M. Kaplan, MD, PhD
• Age, Sex, and Ethnicity—Impact on Muthiah Vaduganathan, MD, MPH From the Mechanism of Action of
Type 1 Diabetes Development Question and Discussion Period Semaglutide 2.4 mg to the STEP
Type 1 Diabetes Incidence by Age and Program
Ethnicity Landmark Trials in Kidney Disease
Melanie J. Davies, CBE, MB, ChB,
Elizabeth J. Mayer-Davis, PhD Landmark Trials in Kidney Disease— MD, FRCP, FRCGP, FMedSci
Type 1 Diabetes Genetic Risk Score by CREDENCE—Lessons Learned from
Results from the STEP Trials in People
Ancestry the First Trial in Nearly Two Decades
with Obesity
Maria Jose Redondo, MD, PhD, MPH to Improve Cardiorenal Outcomes in
Robert F. Kushner, MD
Diabetic Kidney Disease
Type 1 Diabetes Immunopathology Brendon L. Neuen, MBBS (Hons), MSc Cardiometabolic Outcomes in People
across Ancestries with Prediabetes and Type 2 Diabetes
John Kaddis, PhD Landmark Trials in Kidney Disease—
John Wilding, DM, FRCP
DAPA-CKD—Extending the Benefits
Panel Discussion—The Influence of SGLT2 Inhibition to and beyond Clinical Implications of Semaglutide for
of Age, Sex, and Ethnicity on Type 1 Diabetic Kidney Disease Obesity Care
Diabetes David C. Wheeler, MD Lee M. Kaplan, MD, PhD
Elizabeth J. Mayer-Davis, PhD
Maria Jose Redondo, MD, PhD, MPH Question and Discussion Period
John Kaddis, PhD
81ST VIRTUAL SCIENTIFIC SESSIONS | June 25-29, 2021 | #ADA2021 Speakers and presentation titles
are subject to change.
19You can also read
